Special Seminar: Clinical Translation of Fluorescent Molecular Targeted Imaging Agents

Kimberley Samkoe, Assistant Professor of Surgery, Geisel School of Medicine

Tuesday, November 19, 2019, 3:30–4:30pm

Rm 200, Cummings Hall

Improving the ability of surgeons to accurately visualize tumor tissue and distinguish it with high sensitivity from the normal surrounding tissue has been a long-standing goal of imaging scientists. Fluorescence guided surgery in oncology has gained momentum over the last several decades with the development of clinic-ready imaging systems and the exploitation of molecular targeted proteins and therapeutics. Thousands of fluorescent targeted molecules, proteins, and nanoparticles are being developed and tested in pre-clinical models of cancer; however, a bottleneck exists in the development pipeline that restricts the translation of these agents into the clinic. A significant contributor to this bottleneck is the relationship between the physical properties of the imaging agent and the requirements needed for Food and Drug Administration (FDA) approval and realistic implementation into the clinical workflow. Here, I will review my recent experience with a small, fluorescent peptide called ABY-029 that targets epidermal growth factor receptor. I will discuss how the molecular properties of ABY-029—including plasma and tissue pharmacokinetics, ligand-receptor binding kinetics, tissue and organ toxicity, and long-term stability—affect the logistics of clinical integration. In addition, I will present recent work exploring multi-agent imaging cocktails to improve the sensitivity and specificity of tumor detection and the future implications and limitations of translating these combined agents.

About the Speaker

Kimberley Samkoe is assistant professor of surgery at Geisel School of Medicine and adjunct assistant professor of engineering. She obtained her PhD in biophysical chemistry from the Department of Chemistry at the University of Calgary, Alberta, Canada and completed her post-doctoral training in biomedical engineering at Thayer before joining Geisel and Dartmouth-Hitchcock as faculty. Dr. Samkoe’s current research program involves the clinical translation of molecular targeted fluorescence imaging agents for quantitative detection of tumors and therapeutic monitoring of treatment response. In addition, Samkoe has extensive experience in xenograft models of human cancer, Good Laboratory Practices toxicity and stability testing of imaging agents for human translation, photodynamic therapy, and multi-photon spectroscopy.

For more information, contact Marge Heggison at marge.heggison@dartmouth.edu.